Free Trial
→ The Iran War Just Broke the Gold Market (From Behind the Markets) (Ad)tc pixel
NASDAQ:ALT

Altimmune Q1 2026 Earnings Report

Altimmune logo
$3.19 +0.13 (+4.35%)
As of 12:25 PM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Altimmune EPS Results

Actual EPS
N/A
Consensus EPS
-$0.25
Beat/Miss
N/A
One Year Ago EPS
N/A

Altimmune Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.00 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Altimmune Announcement Details

Quarter
Q1 2026
Date
5/12/2026
Time
Before Market Opens
Conference Call Date
Wednesday, May 13, 2026
Conference Call Time
8:30AM ET

Conference Call Resources

Altimmune Earnings Headlines

Altimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026
 |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/06/3288706/0/en/altimmune-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-13-2026.html
Altimmune secures $225M to test GLP-1 in liver disease, eyes first commercial product launch
April 27, 2026  |  bizjournals.comhttps://www.bizjournals.com/washington/news/2026/04/27/altimmune-glp-1-225m-gaithersburg-deep-track.html
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
May 6 at 1:00 AM  |  InvestorPlace (Ad)
Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities
April 27, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/27/3281472/0/en/altimmune-announces-closing-of-225-million-oversubscribed-public-offering-of-securities.html
Here is Why Altimmune Inc. (ALT) Appears to be an Attractive Penny Stock
April 26, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/why-altimmune-inc-alt-appears-151312191.html
Why is Altimmune stock falling today?
April 23, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/why-is-altimmune-stock-falling-today/ar-AA21yDoO
See More Altimmune Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Altimmune? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Altimmune and other key companies, straight to your email.

About Altimmune

Altimmune (NASDAQ:ALT) is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose. This candidate is being advanced in collaboration with the University of Alabama at Birmingham and is supported by the National Institute of Allergy and Infectious Diseases. In parallel, Altimmune’s HepTcell program aims to treat chronic hepatitis B by eliciting targeted T-cell responses capable of clearing infected liver cells.

Altimmune’s AdCOVID™ platform uses a replication-incompetent adenovirus vector to deliver vaccine antigens directly to the nasal mucosa, and it is also under evaluation for additional respiratory pathogens, including coronaviruses. The company maintains a pipeline of preclinical programs in liver and metabolic diseases, reflecting its commitment to harnessing immunotherapy and vaccine design across multiple therapeutic areas.

The company’s leadership team combines extensive scientific expertise and operational experience in vaccine research and development. Through a strategic blend of translational science and external partnerships, Altimmune seeks to advance innovative therapies that improve patient outcomes and address global health challenges.

View Altimmune Profile
Earnings Tools